- The global Addison's Disease Drug Market is anticipated to gain notable traction during the forecast period, with a CAGR of 8.4% from 2025 to 2032.
- Addison’s disease—characterized by chronic adrenal insufficiency—is often associated with autoimmune destruction of the adrenal cortex, infections, or secondary adrenal insufficiency due to pituitary disorders.
- The market is being supported by the increasing availability of synthetic corticosteroids and mineralocorticoids, enhanced focus on patient-centric dosing solutions, and strategic collaborations among pharmaceutical companies.
- Rising healthcare investments, early diagnosis via ACTH stimulation testing, and expanded access to hormone therapies in low- and middle-income countries are expected to further drive market growth
